Menu
ETF
Annual · values202520242023202220212020201920182017
Operating Cash Flow-22.58 M USD-33.36 M USD-11.98 M USD-22.69 M USD-28.50 M USD-8.94 M USD-5.38 M USD-2.06 M USD-761834 USD
Depreciation & Amortization84000 USD
Stock-Based Compensation9.91 M USD7.61 M USD7.37 M USD7.15 M USD4.80 M USD3.11 M USD4.10 M USD10.00 M USD199556 USD
Capital Expenditures1.04 M USD
Cash Flow from Investing-1.04 M USD-15.00 M USD-100000 USD
Cash Flow from Financing27.61 M USD18.21 M USD-4.22 M USD729000 USD96.36 M USD23.90 M USD12.21 M USD900000 USD2.06 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-23.62 M USD

Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system. The primary purpose of its research and development efforts is to create treatments that help in managing and potentially curing a range of conditions by targeting innate immune functions. This approach is significant in the medical field, particularly in autoimmune diseases, cancer, and neurodegenerative disorders, where the immune system's regulation can have profound impacts on disease progression and patient outcomes. By harnessing the body's own defense mechanisms, Inmune Bio Inc. aims to advance therapeutic solutions that are both effective and minimize adverse side effects. Operating in a rapidly evolving sector, the company holds an influential role in the biotechnology market, contributing to cutting-edge scientific advancements. By fostering collaborations with research institutions and leveraging its proprietary technologies, Inmune Bio Inc. continues to push the boundaries of immune-based treatments, offering hope for novel applications across different medical conditions.